The business model of XBiotech Inc is focused on developing antibody therapies to treat various diseases. XBiotech utilizes its True HumanTM antibody technology to discover and develop antibodies that target specific diseases and conditions. The company's approach involves isolating and characterizing natural antibodies produced by the human immune system in response to certain diseases. These antibodies are then utilized as potential therapeutic candidates. XBiotech's business model involves conducting preclinical and clinical studies to evaluate the safety and efficacy of their antibody therapies, seeking regulatory approvals, and potentially partnering with pharmaceutical companies for commercialization. The company aims to improve patient outcomes and bring innovative antibody therapies to market.

XBiotech Inc is primarily active in the biotechnology industry.

The main competitors of XBiotech Inc in the market include pharmaceutical companies such as Amgen Inc., Johnson & Johnson, and Eli Lilly and Company.

XBiotech Inc, a biopharmaceutical company, was founded in 2005 and is headquartered in Austin, Texas. With a focus on discovering and developing True Human™ monoclonal antibodies, the company aims to revolutionize the treatment of various diseases, including cancer and inflammatory disorders. XBiotech Inc is known for its unique approach, harvesting antibodies from natural human immune responses instead of artificial means. This innovative technique allows the company to produce exceptionally pure therapeutic antibodies, offering potential benefits to patients. XBiotech Inc's commitment to advancing medical solutions underscores their dedication to improving global healthcare outcomes.

XBiotech Inc has achieved significant milestones since its inception. The company successfully developed and gained FDA approval for its monoclonal antibody therapy, Xilonix, which targets inflammatory conditions. Additionally, XBiotech Inc performed a successful Phase III clinical trial for Xilonix in advanced colorectal cancer patients. Moreover, the company has expanded its pipeline by initiating clinical trials for other conditions such as Hidradenitis Suppurativa. XBiotech Inc has also established important collaborations with leading pharmaceutical companies, enhancing its research capabilities and market presence. These achievements highlight XBiotech Inc's commitment to innovation, clinical excellence, and dedication to improving the lives of patients.

XBiotech Inc is primarily present in the United States, focusing on the development and commercialization of innovative therapies for various diseases.

XBiotech Inc represents values of innovation, patient-centeredness, and scientific rigor. The company's corporate philosophy revolves around developing groundbreaking therapies to improve patient outcomes. XBiotech Inc aims to advance the understanding and treatment of diseases by utilizing cutting-edge research and technology. With a focus on delivering customized treatments, the company prioritizes patient needs and strives to make a positive impact on individuals' lives. XBiotech Inc is dedicated to fostering a culture of collaboration, integrity, and ethical practices within the organization. Through its commitment to excellence, XBiotech Inc continues to make significant contributions to the healthcare industry.

7 analysts currently rate the XBiotech stock: 6 recommend buying, 1 holding and 0 selling.

XBiotech Analyst Price Targets 2026

Converted at the current exchange rate, the XBiotech share trades at 2.00 EUR (2.28 USD).

The XBiotech share (XBIT) is listed on 5 stock exchanges, including: NASDAQ (XBIT), Frankfurt (4XB.F), München (4XB.MU), Düsseldorf (4XB.DU), SIX (Zürich) (4XB.SW).

XBiotech Inc is a biopharmaceutical company focused on the discovery and development of therapeutics for serious diseases. The company was founded in 2005 and is headquartered in Austin, Texas. The business model of XBiotech is based on the clinical development and commercialization of monoclonal antibodies for the treatment of cancer and chronic inflammatory diseases. The company produces antibodies against cytokines responsible for inflammatory reactions in the human body. XBiotech has developed a comprehensive approach to antibody discovery based on the identification of natural antibodies from the blood of healthy individuals. These antibodies have already shown the ability to target a variety of diseases and therefore have high potential for the development of new therapeutics. The flagship product of XBiotech is the antibody Xilonix. It has been developed for the treatment of metastatic colorectal cancer and has shown in clinical studies the ability to reduce symptoms and improve quality of life for cancer patients. XBiotech recently completed a Phase III study and plans to submit the antibody for regulatory approval soon. In addition, XBiotech is working on the development of antibodies against other diseases such as Alzheimer's, melanoma, and rheumatoid arthritis. The company has made promising progress in these areas as well. Another important aspect of XBiotech's business model is partnerships with other companies. The company aims to establish strong partnerships with pharmaceutical companies to bring new products to the market together. This allows XBiotech to fully leverage the potential of its technology and provide better treatment for patients worldwide. An example of this is the partnership with Janssen Biotech, a subsidiary of Johnson & Johnson. The two companies are working together on the development of antibodies against the cytokine Interleukin-1a (IL-1a), which is involved in the development of various chronic inflammatory diseases. Furthermore, the production of the antibody is significantly more cost-effective and faster through XBiotech's proprietary technology compared to conventional manufacturing methods. Overall, XBiotech has developed a promising business model based on innovative technology and dedicated research and development. The company has already made significant progress and will continue to make important contributions to the development of new therapies for patients with serious diseases. The answer is: XBiotech Inc is a biopharmaceutical company focused on the discovery and development of therapeutics for serious diseases.

The revenue cannot currently be calculated for XBiotech.

The profit cannot currently be calculated for XBiotech.

The P/E ratio cannot be calculated for XBiotech at the moment.

The P/S cannot be calculated for XBiotech currently.

The Eulerpool Quality Score for XBiotech is 2/10.

The ISIN of XBiotech is CA98400H1029. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of XBiotech is A14QF1. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of XBiotech is XBIT. The ticker symbol is used to trade XBiotech shares on the stock exchange.

The current dividend yield of XBiotech is 109.65 %.

XBiotech paid dividends every year for the past 0 years.

XBiotech is assigned to the 'Health' sector.

To receive the latest dividend of XBiotech from amounting to 2.5 USD, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

The dividends of XBiotech are distributed in USD.